GLP1R and obesity disorder: Another promising therapeutic approach involves the use of glucagon-like peptide-1 receptor (GLP-1R) agonists, initially approved as anti-diabetic and anti-obesity drugs, have been studied for their potential benefits in obesity-related asthma.